CClinicalTrials.gg
RecruitingNCT06281522EchinococcusisUpdated Feb 28, 2024

The Importance of Inflammatory Markers Calculated From Preoperative and Postoperative Peripheral Blood Results in the Diagnosis and Treatment of Patients Operated for Hydatid Cyst of the Lung (Lung Echinococcus Granulosus)

An observational study in Lung Hydatid Cyst, sponsored by Abdullah Adiyaman. Recruiting at 1 site in Turkey. Open to participants aged 18 Years to 83 Years. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by Abdullah Adiyaman · Observational

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
54
Ages
18 Years to 83 Years
Sex
All
01

Study summary

This study aims to investigate the role of these laboratory findings in the differential diagnosis and management of pulmonary hydatid cyst (PHC) by examining the number of euzonophils, neutrophils, lymphocytes, platelets and neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and systemic immune inflammatory index values in the peripheral blood of patients diagnosed with pulmonary hydatid cyst (PHC) in the preoperative period and post-operative 3rd month. Although we have extensive data on hydatid liver cysts, there is limited information in the literature on the laboratory values of patients with PHC. This study aims to provide more scientific basis for the diagnosis and management of PHC and is considered as an inexpensive, reproducible and easily calculable method to improve the accurate diagnosis and management of AKH in clinical practice.

Read the detailed description

Hydatid cyst of the lung (HCC) is a health problem caused by a small species of tapeworm called Echinococcus granulosus, a parasitic infection that can occur in humans and other mammals. Hydatid cysts are cysts caused by the larvae of the parasite. They most commonly form in the liver and lungs, but can also occur in other organs. E. granulosus lives in the intestines of animals and excretes them in their feces. Humans can get the eggs of this parasite through contact or under poor hygiene conditions. The ingested eggs hatch in the stomach and intestine and the larvae enter the bloodstream, then form cysts in various organs throughout the body.

Cystic echinococcosis is a disease in which a large group of patients live in conditions of material and social poverty. The disease has a widespread distribution worldwide and the regions with high disease prevalence are Southeast Europe, the Middle East, North, Central and East Asia and South America.

02

Conditions studied

  • Lung Hydatid Cyst

Keywords

  • Lung Hydatid Cyst
  • neutrophils,
  • lymphocytes,
  • platelets
03

Who can participate

Ages eligible
18 Years to 83 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Peripheral blood results of patients hospitalized in the thoracic surgery clinic of S.B.Ü Van Training and Research Hospital due to hydatid cyst of the lung (surgery) will be evaluated.

Inclusion criteria

  • Between January 1, 2022 - December 1, 2023, patients with hydatid cyst of the lung who were hospitalized in the Thoracic Surgery Service

Exclusion criteria

Exclusion Criteria:

  • Between January 1, 2022 and December 1, 2023, other patients admitted to the Thoracic Surgery Service
04

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
54 participants (estimated)
Patient registry
No

Interventions

  • OtherOperated patients with hydatid cyst of the lung

    File screening and blood test results will be evaluated

    Also known as: File screening and blood test results will be evaluated

05

What researchers measure

Primary outcomes

  1. Calculation of laboratory markers

    euzonophil (10\^9/L) , neutrophil (10\^9/L), lymphocyte (10\^9/L), platelet (10\^3/uL) counts and neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, systemic immune inflammatory index (SII = P × N/L) values calculated using these data in the peripheral blood results of patients diagnosed with pulmonary hydatid cyst (PHC) in the pre-operative period and post-operative 3rd month will be examined retrospectively.

    Time frame: 2 monts

06

Study locations

1 of 1 sites recruiting
  • University of Health Sciences, Van Training and Research Hospital
    Van, Turkey
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06281522
Lead sponsor
Abdullah Adiyaman
Responsible party
Abdullah Adiyaman (Graduate Student, Yuzuncu Yıl University) — Sponsor-investigator
First posted
Feb 28, 2024
Start date
Dec 18, 2023
Primary completion
Mar 30, 2024 (estimated)
Completion
Jun 30, 2024 (estimated)
Last update
Feb 28, 2024

Study contacts

Abdullah ADIYAMAN
Contact
aadyaman@hotmail.com
+905465880056
Suleyman Gokalp Gunes
Contact
gokalpgunes@yahoo.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion